Belite Bio, Inc (BLTE)
NEGATIVEFundamental
~26
Price
$162.31
Market Cap
$6.44B
Part 1 · What the company is worth
Overview
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an retinol binding protein 4 oral therapy, which is in preclinical development targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, as well as gout. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Limited financial data available (33% of metrics). Scores may not accurately reflect this company's fundamentals.
Balance Sheet & Liquidity
Revenue
0
Fiscal year ended 12/31/2025
Net Income
$-78M
Fiscal year ended 12/31/2025
Free Cash Flow
-
Total Equity
$777M
Total Liabilities
0
Current Ratio
33.56
Interest Coverage
-
Debt/EBITDA
-
Earnings Per Share
Revenue & Net Income
Free Cash Flow
Income Breakdown
Historical statement
Margins over time
Debt over time
How heavy the debt is
Growth grid
Growth — Revenue
Fair Value Estimation
Fair Value
$214.00
Current Price
$162.31
Margin of Safety
+24.2%
Fair Value Range
$203.30 - $224.70
Estimation Methods
Valuation Metrics
P/E Ratio
-
ROE
-22.1%
P/B Ratio
8.11
P/FCF
-
Gross Margin
0.0%
ROIC
-
Profitability Radar
Value Creation (Economic Moat)
ROIC
-
WACC
8.0%
ROIC − WACC
-
Fundamental Analysis Criteria
Passed (3)
- Price CAGR 52.03%
- Current Ratio
- Analyst Consensus 93% Buy
Failed (6)
- Gross Margin 0.0%
- P/B Ratio 8.11
- DCF valuation (Unknown)
- ROE -26.9%
- Earnings Surprise avg -19.7%
- Piotroski F-Score 0/9
Unavailable (18)
- EPS data insufficient
- ROIC NaN%
- P/FCF NaN
- Dividend Payout NaN%
- Debt/Equity ratio
- Operating Margin NaN%
- Positive Free Cash Flow
- CapEx intensity
- Interest Coverage
- Debt/EBITDA
- Return on Tangible Assets
- Low reliance on intangibles
- Price below Graham Number
- Revenue Growth 5Y (Finnhub)
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
- Share Dilution (missing shares data)
- Net Margin Trend (invalid data)
Piotroski F-Score
Serious financial concerns
Earnings Quality
Low quality: investigate accounting
Share Dilution
Buying back shares. Shareholder friendly
Governance
Executive Team
| Name | Title | Age |
|---|---|---|
| Dr. Yu-Hsin Lin M.B.A., Ph.D. | Chairman of the Board of Directors & CEO | 47 |
| Mr. Hao-Yuan Chuang C.F.A., F.R.M., M.B.A. | CFO & Director | 41 |
| Dr. Nathan L. Mata Ph.D. | Chief Scientific Officer | 59 |
| Dr. Hendrik P.N. Scholl M.A., M.D., Ph.D. | Chief Medical Officer | 56 |
Part 2 · The price and when to enter
This part won't tell you whether the company is worth owning: it helps you choose when to buy it, once the fundamentals have convinced you. Inside: technical analysis, potential, historical drawdowns, gamma exposure.
Latest News
Recent headlines for BLTE, sourced from Markets Gazette.
- 3/3/2026NEUTRALBelite Bio (BLTE) Q4 2025 Earnings Call Transcript
Belite Bio (BLTE) investors are awaiting crucial details following the announcement of the Q4 2025 earnings call transcript. Although the event was reported, the actual content of the transcript is not yet available. This lack of information prevents analysts and investors from assessing the company's financial performance, future outlook, or any significant announcements that could impact the stock's value. Transparency is key for the market, and the absence of concrete data keeps the stock in a phase of uncertainty, with operators eagerly awaiting details to formulate forecasts and make informed decisions.
via Markets Gazette